Management of intraductal papillary mucinous neoplasm is controversial, and several guidelines have aimed to establish an adequate strategy for surgical resection and surveillance. We compared various intraductal papillary mucinous neoplasm guidelines and considered new matters that are pivotal for improved treatment of intraductal papillary mucinous neoplasm. We identified and compared 11 published guidelines, three of which were major guidelines that mainly referred to the diagno- 
may develop distinct pancreatic ductal adenocarcinoma (PDAC) synchronously or metachronously. The natural history and high incidence of BD-IPMN make its surveillance controversial. Hence, several guidelines have been developed with an aim to establish an adequate strategy for surgical resection and surveillance of IPMN. We identified 11 available guidelines and further compared three major guidelines of IPMN published by the International Association of Pancreatology in 2012 (IAP2012), 11 European Study Group on Cystic Tumours of the Pancreas in 2013 (EURO), 12 and American Gastroenterological Association in 2015 (AGA). 13 We also herein present a discussion of new topics that are pivotal for the next step in improving the surveillance and treatment of IPMN.
| COMPARISON OF CURRENT
GUIDELINES FOR IPMN Table 1 shows 11 published guidelines concerning IPMN. Although they include other pancreatic lesions such as cystic neoplasms or pancreatic intraepithelial neoplasia, most of them focus mainly on management of IPMN. Among them, three guidelines deal with pathological issues (#1, #10, #11). [14] [15] [16] An illustrated consensus (#1)
proposed a pathological definition of IPMN for differentiation from pancreatic intraepithelial neoplasia. 16 A revised classification system and recommendations (#10) used the two-tier grading system (lowgrade/high-grade) instead of the three-tier grading system (low-
grade/intermediate-grade/high-grade) proposed by the Armed Forces
Institutes of Pathology. 15, 17 The Recommendation of Verona consensus meeting (#11) provided the principles of pathological evaluation and reporting of IPMN. 14 The American Society for Gastrointestinal Endoscopy guideline (#2) discussed the use of endoscopic modalities, such as endoscopic ultrasonography (EUS), EUS-guided fine-needle aspiration (EUS-FNA), and endoscopic retrograde cholangiopancreatography (ERCP), in differentiating IPMN from other cystic pancreatic lesions. 18 In 2006, international consensus guidelines (the IAP2006) (#3) were the first comprehensive guidelines referring to the diagnosis, indications for resection, and surveillance of IPMN. 19 The Society for Surgery of the Alimentary Tract Patient Care Guidelines (#4) provided general information on the categories, symptoms, diagnosis, and treatment of cystic neoplasms of the pancreas; however, these guidelines were unable to indicate either definite criteria for surgical resection or a surveillance strategy. 20 The consensus statements of the International Cancer of the Pancreas Screening consortium summit (#6) proposed that IPMN was a potential target for early detection and treatment in individuals at high risk for pancreatic cancer. 21 Italian consensus guidelines (#8) mainly focused on the diagnostic and follow-up strategies of pancreatic cystic neoplasms. 22 The remaining three guidelines (#5, #7, #9) are the current comprehensive guidelines citing diagnostic work-up, indications for surgery, surveillance after surgery, and surveillance of non-resected IPMN. [11] [12] [13] In this section, we compare these three guidelines ( Table 2 ). The IAP2012 (#5) and EURO (#7) guidelines are expert consensuses, whereas the AGA guidelines (#9) were established by an evidence-based approach using the GRADE (Grading of Recom- 
| PRED ICTION OF MALIGN ANT IPMN BY NOMOGRAM
Besides expert opinion-based guidelines, several efforts have been made to establish a nomogram as a more rational system with which to predict malignant IPMN, as listed in Table 3 . 8,25-29 Shimizu et al. 27 first reported a nomogram for IPMN, which covered both MD-IPMN and BD-IPMN simultaneously. Jang et al. 8 included the largest clinicopathological data set of 645 patients and focused exclusively on BD-IPMN. Correa-Gallego et al. 25 and Attiyeh et al. 26 devised two independent nomograms for MD-IPMN and BD-IPMN, respectively. In these three nomograms, which contain an independent nomogram exclusively for BD-IPMN, cyst size and existence of a solid component are common predictors of malignant lesions in BD-IPMN, 8, 25, 26 and older age is also a predictor in two nomograms. 8, 26 Gemenetzis et al. 29 included both MD-IPMN and BD-IPMN in a nomogram, and one of its factors predicting invasive cancer is the neutrophil-to-lymphocyte ratio, which has been reported to be a predictor of invasive cancer and poor prognosis in patients with various types of tumors. [30] [31] [32] [33] These nomograms were validated by two methods: internal validation and external validation (Table 3) . External evaluation of the nomogram is recommended because of objectivity and repeatability. 34 Three studies assessed their nomograms by external validation, 8, 26, 28 and one study used internal validation, 25 and one used no validation. 29 The concordance index and area under the curve derived from validation are used to estimate validity of the nomo- (Table 4) .
T A B L E 2 Comparison of the guidelines citing diagnostic work-up, indications for surgery, surveillance after surgery, and surveillance of nonresected IPMN
International consensus guidelines 2012 (IAP2012) 11 European Experts Consensus Statement (EURO) 12 American Gastroenterological Association Institution Guideline (AGA) 48 These data indicate that long-term surveillance (as long as the patient is fit for surgery) is required to detect remnant pancreatic lesions.
Hirono et al. 41 reported that a candidate risk factor for these remnant pancreatic lesions was dysplasia at the pancreatic cut margin, which included not only malignant lesions but also low-grade lesions. Pea et al. 51 than that of malignant transformation of BD-IPMN (0.0-3.0%) [52] [53] [54] [55] ( Table 5 ). Thus, attention should be paid not only to malignant transformation of IPMN itself, but also to the development of concomitant PDAC during surveillance for BD-IPMN. In addition, surveillance carried out at shorter intervals might be needed to detect concomitant PDAC because Uehara et al. 54 reported that most concomitant PDAC were discovered at an advanced stage or in an unresectable condition during their surveillance of IPMN despite carrying out surveillance every 3-6 months.
Another important issue is how long the surveillance should be continued in terms of detecting PDAC concomitant with IPMN. The AGA guidelines suggest that patients without significant changes in their pancreatic cyst for 5 years can discontinue surveillance. However, in their long-term surveillance of BD-IPMN without pancreatectomy, Tanno et al. 55 reported that the 5-and 10-year cumulative incidences of the development of PDAC distinct from BD-IPMN were 3.0% and 8.8%, respectively. These findings suggest that surveillance of IPMN should be continued for more than 5 years even when the IPMN shows no significant morphological change.
Considering the high incidence of IPMN, the estimated prevalence of which is approximately 26/100 000 and increases three-to fourfold in individuals older than 60 years, 56, 57 determination of patients at high risk of developing distinct PDAC is urgently needed.
One possible risk factor is a family history of PDAC. Nehra et al. 58 showed that concurrent PDAC in patients who underwent resection of IPMN were more commonly observed in those with than in those without a family history of PDAC (11.1% vs 2.9%, respectively;
P=.02). Meanwhile, Mandai et al. 59 showed that the frequency of concomitant PDAC in patients with BD-IPMN or mixed IPMN was significantly higher in patients with than in those without a family history; however, median age of the patients with a family history was significantly higher than in those without a family history. To exclude the influence of age, Mandai et al. carried out another comparison in which they limited the age of patients to ≥70 years and, as a result, the frequency of concomitant PDAC was not significantly different between these two groups.
Although several Japanese investigators 2,53 have recommended carrying out surveillance every 6 months for detection of PDAC concomitant with IPMN, the diagnostic modality that should be included in this protocol remains unclear. Alternating CT and MRCP twice a year seems to be a popular protocol in Japan, 60 but it often fails to diagnose resectable PDAC. 61 Conversely, Kamata et al. In summary, it might be important to carry out long-term surveillance at short intervals for more than 5 years as long as the patient is fit for surgery. A common protocol for IPMN with and without resection is alternate CT and MRCP (EUS) twice a year in Japan; 60 however, its ability to improve overall survival and its cost-effectiveness should be evaluated. Further investigation using a prospective protocol with a large number of patients is needed to clarify the precise incidence of concomitant PDAC distinct from IPMN, to establish the optimal interval and period of surveillance, and to determine the most reliable risk factors for concomitant PDAC.
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